Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907701 | 0.91 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1USP2CYP3A4CYP2D6 | |
| SCHEMBL2905003 | 0.88 | SIRT1 (0.38) | PTK2SMN1; SMN2ALDH1A1SIRT1MEN1 | |
| SCHEMBL2904802 | 0.87 | P4HB (0.38) | PTK2SMN1; SMN2ALDH1A1KCNH2SIRT1 | |
| SCHEMBL2909335 | 0.86 | HRH3 (0.43) | SMN1; SMN2ALDH1A1CHRM2HTR1AADRA2A | |
| SCHEMBL2901687 | 0.86 | TSHR (0.38) | PTK2SMN1; SMN2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2902357 | 0.86 | HRH3 (0.37) | SMN1; SMN2ALDH1A1CHRM2HTR1AADRA2A | |
| SCHEMBL2907051 | 0.85 | ALDH1A1 (0.41) | PTK2SMN1; SMN2ALDH1A1USP2SIRT1 | |
| SCHEMBL2901965 | 0.83 | SCD5 (0.42) | ALDH1A1USP2CYP3A4KDM4ELMNA | |
| SCHEMBL2908342 | 0.82 | ITGB2 (0.38) | PTK2SMN1; SMN2ALDH1A1USP2SIRT1 | |
| SCHEMBL2904606 | 0.80 | P2RX3 (0.37) | ALDH1A1CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | PTK2 4083/4885SMN1; SMN2 1277/4885ALDH1A1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.